» Articles » PMID: 18219560

Stereoselective Metabolism of Bupropion by Cytochrome P4502B6 (CYP2B6) and Human Liver Microsomes

Overview
Journal Pharm Res
Specialties Pharmacology
Pharmacy
Date 2008 Jan 26
PMID 18219560
Citations 25
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: Hydroxylation of the antidepressant and smoking deterrent drug bupropion is a clinically important bioactivation and elimination pathway. Bupropion hydroxylation is catalyzed selectively by cytochrome P4502B6 (CYP2B6). CYP2B6-catalyzed bupropion hydroxylation has been used as an in vitro and in vivo phenotypic probe for CYP2B6 activity and CYP2B6 drug interactions. Bupropion is chiral, used clinically as a racemate, and disposition is stereoselective. Nevertheless, it is unknown whether CYP2B6-catalyzed bupropion hydroxylation is stereoselective.

Methods: Hydroxylation of racemic bupropion by recombinant CYP2B6 and human liver microsomes was evaluated using a stereoselective assay.

Results: At therapeutic concentrations, hydroxylation of (S)-bupropion was threefold and 1.5-greater than (R)-bupropion, respectively, by recombinant CYP2B6 and human liver microsomes. In vitro intrinsic clearances were likewise different for bupropion enantiomers.

Conclusions: Stereoselective bupropion hydroxylation may have implications for the therapeutic efficacy of bupropion as an antidepressant or smoking cessation therapy, and for the use of bupropion as an in vivo phenotypic probe for CYP2B6 activity.

Citing Articles

Physiologically Based Pharmacokinetic Model of CYP2D6 Associated Interaction Between Venlafaxine and Strong Inhibitor Bupropion-The Influence of Age-Relevant Changes and Inhibitory Dose to Classify Therapeutical Success and Harm.

Luecht U, Scholz W, Geiben A, Haen E, Hempel G Pharmaceutics. 2025; 17(2).

PMID: 40006546 PMC: 11858960. DOI: 10.3390/pharmaceutics17020179.


Pharmacogenetic Influence on Stereoselective Steady-State Disposition of Bupropion.

Kharasch E, Lenze E Drug Metab Dispos. 2024; 52(5):455-466.

PMID: 38467432 PMC: 11023817. DOI: 10.1124/dmd.124.001697.


A scoping review of smoking cessation pharmacogenetic studies to advance future research across racial, ethnic, and ancestral populations.

Prom-Wormley E, Wells J, Landes L, Edmondson A, Sankoh M, Jamieson B Front Genet. 2023; 14:1103966.

PMID: 37359362 PMC: 10285878. DOI: 10.3389/fgene.2023.1103966.


Characterization of the Stereoselective Disposition of Bupropion and Its Metabolites in Rat Plasma and Brain.

Bhattacharya C, Masters A, Bach C, Sinn A, Trowbridge M, Stratford Jr R Eur J Drug Metab Pharmacokinet. 2023; 48(2):171-187.

PMID: 36823342 DOI: 10.1007/s13318-023-00817-9.


.

Gufford B, Metzger I, Bamfo N, Benson E, Masters A, Lu J J Pharmacol Exp Ther. 2022; 382(3).

PMID: 35798386 PMC: 9426761. DOI: 10.1124/jpet.122.001277.


References
1.
Kharasch E, Mitchell D, Coles R . Stereoselective bupropion hydroxylation as an in vivo phenotypic probe for cytochrome P4502B6 (CYP2B6) activity. J Clin Pharmacol. 2008; 48(4):464-74. DOI: 10.1177/0091270008314254. View

2.
Ekins S, Wrighton S . The role of CYP2B6 in human xenobiotic metabolism. Drug Metab Rev. 1999; 31(3):719-54. DOI: 10.1081/dmr-100101942. View

3.
Kharasch E, Hoffer C, Whittington D, Sheffels P . Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and miotic effects of methadone. Clin Pharmacol Ther. 2004; 76(3):250-69. DOI: 10.1016/j.clpt.2004.05.003. View

4.
Bondarev M, Bondareva T, Young R, Glennon R . Behavioral and biochemical investigations of bupropion metabolites. Eur J Pharmacol. 2003; 474(1):85-93. DOI: 10.1016/s0014-2999(03)02010-7. View

5.
Hesse L, Venkatakrishnan K, Court M, von Moltke L, Duan S, Shader R . CYP2B6 mediates the in vitro hydroxylation of bupropion: potential drug interactions with other antidepressants. Drug Metab Dispos. 2000; 28(10):1176-83. View